regulatory
confidence high
sentiment neutral
materiality 0.55
Intelligent Bio Solutions updates FDA 510(k) timeline; clearance expected H2 2026
INTELLIGENT BIO SOLUTIONS INC.
- Will commence clinical studies before year-end to gather additional data for FDA 510(k) resubmission for codeine fingerprint test.
- Anticipates FDA 510(k) clearance for opiate codeine use in the second half of 2026.
- Drug screening system adopted by over 450 accounts in 24 countries with 18 distribution partners.
- Currently marketed outside U.S. and for forensic use only; FDA clearance would open broader U.S. commercial entry.